Zeesan Overview
- Year Founded
-
2010
- Status
-
Private
- Employees
-
390
- Latest Deal Type
-
IPO
- (Cancelled)
- Investors
-
7
Zeesan General Information
Description
Developer and producer of molecular diagnostics related kits, instruments and reagents with the underlying PCR technology. The company is committed to the development and marketing the best products for molecular diagnostics and it has established "Multicolor Melting Curve Analysis", "Magnetic Bead (MB)-based Nucleic Acid Extraction Platform" and "Automatic Instrumentation Integration Platform". , filling the gaps in many domestic PCR subdivision tracks.
Contact Information
Website
www.zsandx.comCorporate Office
- Building 1, 3701 Xiang'an North Road
- Torch Hi-Tech Industrial Development Zone (Xiang'an)
- Xiamen, Fujian 361101
- China
Corporate Office
- Building 1, 3701 Xiang'an North Road
- Torch Hi-Tech Industrial Development Zone (Xiang'an)
- Xiamen, Fujian 361101
- China
Zeesan Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. IPO | 29-Jun-2023 | Cancelled | Profitable | |||
| 7. Secondary Transaction - Private | 13-Jul-2021 | Completed | Profitable | |||
| 6. Secondary Transaction - Private | 01-Jan-2019 | Completed | Profitable | |||
| 5. Secondary Transaction - Private | 01-Jan-2016 | Completed | Profitable | |||
| 4. Later Stage VC | 28-Jul-2015 | Completed | Generating Revenue | |||
| 3. IPO | 09-Dec-2014 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 14-Apr-2014 | $1.63M | $2.43M | Completed | Generating Revenue | |
| 1. Early Stage VC | 07-Feb-2012 | $791K | $791K | Completed | Generating Revenue |
Zeesan Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | ||||||||
| Ordinary Shares | ||||||||
| Ordinary Shares | 408,000 | $1.97 | $1.97 | 1x | $1.97 | 3.68% |
Zeesan Patents
Zeesan Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4279573-A1 | Device, kit and method for extracting nucleic acids | Pending | 12-Jan-2021 | ||
| EP-4279573-A4 | Device, kit and method for extracting nucleic acids | Pending | 12-Jan-2021 | ||
| US-20240052335-A1 | Device, kit and method for extracting nucleic acids | Pending | 12-Jan-2021 | ||
| WO-2022151640-A1 | Device, kit and method for extracting nucleic acids | Inactive | 12-Jan-2021 | ||
| EP-4276168-A1 | Reagent container and operation method therefor, and reagent treatment system | Pending | 08-Jan-2021 | B01L3/50825 |
Zeesan Signals
Zeesan Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Sinovation Ventures | Venture Capital | Minority | ||
| Dirui | Corporation | Minority | ||
| CITIC Securities | Investment Bank | Minority | ||
| Mingdao Investment | Growth/Expansion | Minority | ||
| Shengyu Investment | Growth/Expansion | Minority |
Zeesan FAQs
-
When was Zeesan founded?
Zeesan was founded in 2010.
-
Where is Zeesan headquartered?
Zeesan is headquartered in Xiamen, China.
-
What is the size of Zeesan?
Zeesan has 390 total employees.
-
What industry is Zeesan in?
Zeesan’s primary industry is Diagnostic Equipment.
-
Is Zeesan a private or public company?
Zeesan is a Private company.
-
What is Zeesan’s current revenue?
The current revenue for Zeesan is .
-
How much funding has Zeesan raised over time?
Zeesan has raised $7.38M.
-
Who are Zeesan’s investors?
Sinovation Ventures, Dirui, CITIC Securities, Mingdao Investment, and Shengyu Investment are 5 of 7 investors who have invested in Zeesan.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process